Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations.
Alexander K TsaiSana KagalwallaJenna LangerThuy Le-KumarVikas Le-KumarEmmanuel S AntonarakisPublished in: Expert opinion on biological therapy (2024)
Pembrolizumab has not benefitted unselected metastatic prostate cancer patients when combined with chemotherapy, next-generation hormonal agents (NHA), or poly(ADP-ribose) polymerase inhibitors (PARPi). PD-L1 positivity does not predict the response to pembrolizumab in this disease. A small number of responding patients can likely be explained by rare genetic and molecular defects, and more innovative combination strategies are needed to improve outcomes in prostate cancer patients who are not sensitive to pembrolizumab. Emphasis should be placed on developing additional or alternative immuno-oncology approaches beyond classical immune checkpoint inhibition.
Keyphrases
- prostate cancer
- advanced non small cell lung cancer
- squamous cell carcinoma
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- ejection fraction
- radical prostatectomy
- chronic kidney disease
- peritoneal dialysis
- palliative care
- genome wide
- polycystic ovary syndrome
- patient reported outcomes
- dna methylation
- skeletal muscle
- patient reported
- copy number